Prostate-specific antigen induces apoptosis of osteoclast precursors: Potential role in osteoblastic bone metastases of prostate cancer

Prostate

Volumn 66, Issue 15, 2006, Pages 1573-1584

  Goya, Masato ^a   Ishii, Genichiro ^a   Miyamoto, Shinichi ^a   Hasebe, Takahiro ^a   Nagai, Kanji ^b   Yonou, Hiroyuki ^c   Hatano, Tadashi ^c   Ogawa, Yoshihide ^c   Ochiai, Atsushi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Apoptosis; Osteoblastic bone metastasis; Osteoclast precursors; Prostate cancer; Prostate specific antigen

Indexed keywords

ACID PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; TARTARIC ACID;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE METASTASIS; CELL MATURATION; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL STRUCTURE; CONTROLLED STUDY; ENZYME ACTIVITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; PROSTATE CANCER; SCID MOUSE; TUMOR CELL LINE;

ADENOCARCINOMA; AGED; ANIMALS; APOPTOSIS; BONE NEOPLASMS; BONE TRANSPLANTATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DNA FRAGMENTATION; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; OSTEOBLASTS; OSTEOCLASTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RNA, MESSENGER; SPECIFIC PATHOGEN-FREE ORGANISMS; STEM CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33750474096     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20375     Document Type: Article

References (41)

1. Abrams H, Spiro R, Goldstein N. Metastases in carcinoma: Analysis of 1000 autopsied cases. Cancer 1950;3:74-85.
2. Rana A, Chisholm GD, Khan M, Sekharjit SS, Merrick MV, Elton RA. Patterns of bone metastasis and their prognostic significance in patients with carcinoma of the prostate. Br J Urol 1993;72:933-936.
3. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum Pathol 2000;31:578-583.
4. Clarke NW, McClure J, George NJR. Osteoblast function and osteomalacia in metastatic prostate cancer. Eur Urol 1993;24: 286-290.
5. Mansson PE, Adams P, Kan M, McKeehan WL. HBGF1 gene expression in normal rat prostate and two transplantable rat prostate tumors. Cancer Res 1989;49:2485-2494.
6. Rabbani SA, Desjardins J, Bell AW, Banville D, Mazar A, Henkin J, Goltzman D. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun 1990;173: 1058-1064.
7. Bentley H, Hamdy FC, Hart KA, Seid JM, Williams JL, Johnstone D, Russell RG. Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 1992;66:1159-1163.
8. Killian CS, Corral DA, Kawinski E, Constantine RI. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGFb and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun 1993;192: 940-947.
9. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;9:944-949.
10. Yonou H, Yokose T, Kamijo T, Kanomata N, Hasebe T, Nagai K, Hatano T, Ogawa Y, Ochiai A. Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. Cancer Res 2001;61:2177-2182.
11. Yonou H, Aoyagi Y, Kanomata N, Kamijo T, Oda T, Yokose T, Hasebe T, Nagai K, Hatano T, Ogawa Y, Ochiai A. Prostate-specific antigen induces osteoplastic changes by an autonomous mechanism. Biochem Biophys Res Commun 2001;289:1082-1087.
12. Lilja H, Oldbring J, Rannevik G, Laurell CB. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Investig 1987;80:281-285.
13. Cohen P, Graves H, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992;75:1046-1053.
14. Cramer SD, Chen Z, Peehl DM. Prostate-specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: In activation of PTHrP-stimulated cAMP accumulation in mouse osteoblast. J Urol 1996;156:526-531.
15. Aoki J, Yamamoto I, Hino M, Shigeno C, Kitamura N, Itoh H, Torizuka K, Itoh T, Furuta M. Sclerotic bone metastasis: Radiologic- pathologic correlation. Radiology 1986;159:127-132.
16. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate rumor growth in the bone. J Clin Investig 2001;107:1235-1244.
17. Adami S. Bisphosphonates in prostate carcinoma. Cancer 1997; 80:1674-1679.
18. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-580.
19. Cole AA, Walter LM. Tartrate-resistant acid phosphatase in bone and cartilage following decalcification and cold-embedding in plastic. J Histochem Cytochem 1987;35:203-206.
20. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluoresein labeled Annexin V. J Immunol Methods 1995;184:39-51.
21. Izawa M, Kato Y, Iwasaki K. Induction of a receptor-mediated genomic DNA fragmentation in rat thymus following administration of glucocorticoid with different biopotencies: An approach by cell-free system. Endocr J 1997;44:677-688.
22. Simonet WS, Lacey DL, Dunstan CR. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
23. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. Osteoclast differenciation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-3602.
24. Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qin W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess TL, Boyle WJ, Polverino AJ. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000;157:435-438.
25. Marks SCJ. Morphological evidence of reduced bone resorption in osteopetrotic (op) mice. Am J Anat 1982;163:157-167.
26. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM. OPGL is a key regulator of osteoclastogenesis, lymph-node organogenesis. Nature 1999;397:315-323.
27. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ. RANK is intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000;97:1566-1571.
28. larke NM, McClure J, George NJR. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991;68:74-80.
29. cher HI, Chung LW. Bone metastases: Improving the therapeutic index. Semin Oncol 1994;21:630-656.
30. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999;96:3540-3545.
31. Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci USA 1997;94:10057-10062.
32. Catz SD, Johnson JL. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 2001;20:7342-7351,
33. LaCasse EC, Baird S, Korneluk RG, Mackenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998;17:3247-3259.
34. Yoneda T. Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone. Eur J Cancer 1998;34:240-245.
35. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 2000;88:2979-2988.
36. Kahn AJ, Simmons DJ. Investigation of cell lineage in bone using a chimera of chick and quail embryonic tissue. Nature 1975;258: 325-327.
37. Udagawa N, Takahashi N, Akatsu T, Tanaka H, Sasaki T, Nishihara T, Koga T, Martin TJ, Suda T. Origin of osteoclasts: Mature monocytes and macrophages are capable of differentiating into osteoclasts under suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA 1990;87:7260-7264.
38. Young JW, Steinman RM. The hematopoietic development of dendritic cells: A distinct pathway for myeloid differentiation. Stem Cells 1996;14:376-387.
39. Healy CG, Simons JW, Carducci MA, DeWeese TL, Bartkowski M, Tong KP, Bolton WE. Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry 1998;32: 109-119.
40. Salgaller ML, Lodge PA, McLean JG, Tjoa BA, Loftos DJ, Ragde H, Kenny GM, Rogers M, Boynton AL, Murphy GP. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate 1998;35:144-151.
41. Pirtskhalaishvili G, Shurin GV, Gambotto A, Esche C, Wahl M, Yurkovetsky ZR, Robbins PD, Shurin MR. Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice. J Immunol 2000;165:1956-1964.